TELA Bio, Inc. (NASDAQ: TELA)

TELA Bio, Inc. is a commercial-stage medical technology company that develops and sells innovative soft tissue reconstruction solutions. Its products are designed to preserve and restore patient anatomy by combining biologic material derived from ovine rumen with polymer reinforcement. The company focuses on two primary markets: hernia repair and abdominal wall reconstruction, and plastic and reconstructive surgery. In the hernia repair market it offers the OviTex Reinforced Tissue Matrix portfolio which includes configurations for open, laparoscopic and robotic assisted procedures such as OviTex LPR for laparoscopic and robotic assisted use and OviTex IHR for inguinal hernia repair. In the plastic and reconstructive surgery market it offers the OviTex PRS Reinforced Tissue Matrix portfolio with options for short term resorbable, permanent and long term resorbable materials. All products are provided as sterile dry sheets that require brief rehydration before implantation and are intended to reinforce soft tissue where weakness exists.

TELA Bio generates revenue principally from the sale of its OviTex and OviTex PRS reinforced tissue matrices to hospitals and ambulatory surgery centers in the United States, with additional sales in Europe and limited revenue from complementary products such as the LIQUIFIX hernia mesh fixation devices. The company reported revenue of $80.3 million for the year ended December 31, 2025 and $69.3 million for the year ended December 31, 2024 representing a year over year increase of $11.0 million or 16%. The vast majority of revenue to date has been generated from sales of OviTex and OviTex PRS products in the United States with the remainder coming from European sales and other product lines. In September 2023 TELA Bio entered into a distribution agreement with Advanced Medical Solutions Limited to distribute the LIQUIFIX FIX8 and LIQUIFIX Precision hernia mesh fixation devices in the United States and announced the full commercial launch of these devices in March 2024. Earlier the company co developed and commercialized the NIVIS fibrillar collagen pack with Regenity Biosciences and in March 2024 sold its distribution rights to MiMedx Group Inc for an initial $5.0 million payment plus potential future payments ranging from $3.0 million to $7.0 million based on net sales of the product now marketed as HELIOGEN.

Within the hernia repair market TELA Bio competes with established players such as Bard a subsidiary of Becton Dickinson and Company which offers Phasix and Ventralight ST and Allergan an AbbVie subsidiary which markets Strattice. In the plastic and reconstructive surgery arena its rivals include Allergan with AlloDerm MTF Biologics with FlexHD Novadaq with DermACell RTI Surgical with Cortiva Bard with GalaFLEX and Integra Lifesciences with SurgiMend and DuraSorb. The company differentiates itself through its proprietary reinforced tissue matrix technology that interweaves polymer fibers through ovine rumen providing improved handling lower inflammatory response and competitive pricing. Its exclusive supply agreement with Aroa secures a low cost source of biologic material while a broad intellectual property portfolio and clinical data demonstrating low recurrence rates support its market position. Based on the volume weighted average selling price of its OviTex products TELA Bio estimates the annual U. S. total addressable market opportunity for its OviTex portfolio to be approximately $1.8 billion. Based on current sales of biologic matrices in the United States it estimates the annual U. S. current addressable market opportunity for its OviTex PRS products to be approximately $800 million. Clinical evidence from the BRAVO study showed a 24 month recurrence rate of 2.6% for OviTex in primary or recurrent ventral hernias with 38% of patients experiencing surgical site occurrences and 78% of the enrolled cohort classified as high risk for such events. Surgeon satisfaction with the product in the BRAVO study averaged 9.7 out of 10 at 30 days for the minimally invasive cohort and remained consistent over 24 months of follow up. The reinforced tissue matrix design allows for load sharing between biologic material and polymer providing mid term and long term strength while preserving physiologic compliance properties.

TELA Bio serves hospitals ambulatory surgery centers and surgeons who perform soft tissue reconstruction procedures. Its customers also include group purchasing organizations and integrated delivery networks that facilitate broad access to its products. As of December 31, 2025 the company had contracted with three national group purchasing organizations in the United States covering its OviTex and OviTex PRS product lines. In addition to its direct sales force in the United States TELA Bio maintains a small number of sales representatives in the United Kingdom and the European Union and uses independent contractors and distributors in select European countries. The filing does not disclose specific customer names so the base is described by institution type rather than individual entities.